Thrombin has been implicated in the stimulation of smooth muscle cell (SMC) proliferation that contributes to post angioplasty restenosis. The present studies demonstrated that human alpha-thrombin was a potent and efficacious mitogen for cultured rat aortic SMC, stimulating an increase in 3H-thymidine incorporation, as well as an increase in cell number at 1 to 10 nM concentration. gamma-Thrombin, which is enzymatically active but lacks fibrinogen clotting activity, stimulated SMC mitogenesis but was approximately 10-fold less potent than alpha-thrombin. In contrast, D-phenylalanyl-L-propyl-L-arginyl-chloromethyl ketone-alpha-thrombin, which lacked enzymatic activity, had no mitogenic effect. Diisopropylfluorophosphate-alpha-thrombin failed to stimulate mitogenesis except at concentrations having equivalent enzymatic activity as that of alpha-thrombin at its threshold for mitogenesis. Thus, thrombin-induced proliferation was dependent on enzymatic activity. A 14-residue peptide (SFLLRNPNDKYEPF) corresponding to amino acids 42 through 55 of the human thrombin receptor (Vu, T. K., D. T. Hung, V. I. Wheaton, and S. R. Coughlin, 1991 . Cell. 64:1057-1068 had full efficacy in stimulating SMC proliferation. Reversing the first two amino acids of this peptide abolished mitogenic activity. Northern analysis demonstrated that SMC expressed a single mRNA species that hybridized to a labeled thrombin receptor cDNA probe. These findings indicate that alphathrombin stimulates SMC proliferation via the proteolytic activation of a receptor very similar or identical to that previously identified.
Introduction
Percutaneous transluminal coronary angioplasty is a commonly used and effective method for reestablishing adequate blood flow in stenosed coronary arteries. Despite a high early success rate, restenosis occurs in -30-35% ofpatients by 6 mo ( 1 ). Smooth muscle cell (SMC)' proliferation is known to con-tribute to postangioplasty restenosis (2) (3) (4) (5) , and as such there has been extensive interest in identifying the factors that modulate SMC proliferation. The vascular injury induced by angioplasty results in activation of the coagulation cascade which can generate -140 nM concentration of thrombin (6) . The resultant thrombus can serve as a reservoir of active thrombin (7) . Thus, thrombin may have a significant role in the mediation of postangioplasty restenosis. Consistent with this, Sarembock et al. (8) have recently demonstrated that r-hirudin (a specific thrombin inhibitor) reduced restenosis after angioplasty in a rabbit model of focal femoral atherosclerosis. Additionally, a number ofstudies (9-1 1 ), though not all ( 12) , have demonstrated that thrombin is a potent mitogen for SMC as well as other mesenchymal-derived cells (13) (14) (15) .
Vu et al. (16) and Rasmussen et al. (17) cloned a cDNA encoding a functional thrombin receptor that has a novel proteolytic mechanism of activation. Their data demonstrated a signaling mechanism by which thrombin cleaves its receptor's amino terminal region, exposing a new amino terminus that functioned as a tethered ligand to activate the receptor. This receptor is expressed on platelets, endothelial cells ( 16) , and fibroblasts ( 17) . If thrombin's effects as an SMC mitogen are mediated via a similar receptor mechanism, catalytic activity would be essential for mitogenesis. Indeed, catalytic activity is essential for thrombin induced mitogenesis in fibroblasts ( 13). However, Bar Shavit et al. reported that catalytic activity was not necessary for thrombin-induced stimulation ofmitogenesis in bovine aortic SMC (9) . Thus, at present, it is unclear whether the mitogenic effects of a-thrombin in SMC are mediated by receptors that are functionally similar to or distinct from the cloned thrombin receptors.
The objectives of the present study were to determine whether thrombin was mitogenic for cultured SMC and, if so, to determine whether this effect: (a) was blocked by r-hirudin; (b) required the catalytic activity of thrombin; and (c) was mediated by a receptor similar to the thrombin receptor identified by Vu et al. ( 16) and Rasmussen et al. ( 17) .
Methods

Cell culture
SMCs from rat aorta and rabbit femoral arteries were cultured by a modification ofthe method ofOwens et al. ( 18) . Rat ( 18) . After 4 d in SFM, culture medium was replaced and cultures were treated with the growth factor of interest.
Growth factors. Platelet-derived growth factor (PDGF)-BB (Upstate Biotechnology Inc., Lake Placid, NY) was used at a concentration of 10 ng/ml. The PDGF-BB vehicle contained 10 mM acetic acid and 2 mg/ml BSA. The thrombin vehicle was PBS. Hirudin (leech, recombinant, [ Lys-47 ] -rHV2 variant; Sigma Chemical Co.) was used as the thrombin inhibitor.
Thrombin preparations
Human a-thrombin was prepared and evaluated as previously described (19) . Catalytically inactivated diisopropylfluorophosphate (DIP)-a-thrombin and D-phenylalanyl-L-propyl-L-arginyl-chloromethyl ketone (PPACK)-a-thrombin, as well as -y-thrombin were made from a-thrombin ( 13 ) . The a-thrombin preparation used in the present study was 96.2, 3.4, and 0.4% a-, ,B-, and -y-thrombins, respectively, titrated to 88.4% active enzyme, and had a specific clotting activity of 3,500 kilo U.S. NIH units/g. The DIP-and PPACK-a-thrombin possessed 0.18 and 0.00 kU/g, respectively. The y-thrombin consisted of 0.0, 15.1, and 84.9% a-, p3-, and y-thrombins, and was 84.5% active and had 8.2 kU/g. The activation peptide SFLLRNPNDKYEPE and the control isomer FSLLRNPNDKYEPE were synthesized as described ( 16).
[3H] Thymidine incorporation 
Cell counts
Cultures were washed with PBS, harvested into 1 ml oftrypsin/EDTA diluted in 0.9% NaCl (Columbia Diagnostics Inc., Springfield, VA), placed in a vial containing 20 ml of filtered saline, and counted using an Electrozone Celloscope (Particle Data, Inc., Elmhurst, IL).
Northern analysis
Total RNA and poly(A )+ selected RNA were prepared using methods previously described (20, 21) . 30 Mg of total or 3 Mg of poly(A)+ selected RNA were dissolved in RNA loading buffer (0.2 M 3-(4-Morpholino)propane sulfonic acid, 0.05 M sodium acetate, 0.01 M EDTA, 37% formaldehyde, 99% formamide), and electrophoresed for 4 h in 1.2% agarose gel containing 6.7% formaldehyde. The gel was rinsed with water and then neutralized in 20x sodium chloride sodium phosphate EDTA buffer for 30 min before being transferred to a nylon membrane (Micron Separations Inc., Westboro, MA) for 16 h. The filter was exposed to an ultraviolet transilluminator for 90 s, baked for 2 h at 80°C in a vacuum oven, air dried, and stored. Prehybridization, hybridization, and washing protocols were performed as described (22) at 65°C. The probe used in this assay was a cDNA fragment encoding transmembrane domains three through seven of the murine homologue of the previously described human thrombin receptor ( 16 
Results and Discussion
Thrombin is a potent mitogen for aortic SMC in culture. As shown in Fig. 1 , a-thrombin was a very potent and efficacious mitogen for rat aortic SMCs in culture, eliciting a 10-15-fold increase in [3H ] thymidine incorporation between 24 and 48 h after stimulation. a-Thrombin stimulated a maximal mitogenic response at a concentration of 1-10 nM. Extremely high a-thrombin concentrations resulted in a diminished response accompanied by loss of cells from the culture dish. The magnitude of the thrombin-induced growth response was equivalent to that elicited by PDGF-BB, a known potent SMC mitogen (23) , and 60-80% as efficacious as 10% FBS (Fig. 2) . Thrombin-induced increases in DNA synthesis were accompanied by a 60% increase in cell number (data not shown) indicating that thrombin was not simply increasing cell turnover. These results are consistent with previous studies demonstrating thrombin-induced mitogenesis in bovine aortic SMC (9) and SMC isolated from neonatal rat heart ( 11), and results from our laboratory with rabbit SMC (data not shown). In contrast, Berk et al. found that, whereas a-thrombin stimulated many of the same early events as PDGF, such as increases in [Ca2+ ]j, pHi, PtdInsP2 hydrolysis, and c-fos mRNA in adult rat aortic vascular SMC ( 12), a-thrombin did not stimulate cell division. Our studies were performed in a defined serum-free medium whereas those by Berk et al. were done in the presence of 0.4% fetal bovine serum. Indeed, the addition of 0.2% fetal bovine serum to our serum-free media resulted in a two-to fourfold reduction in the thrombin-stimulated increase in DNA synthesis (data not shown). (24) . In our studies, using a defined serum-free medium, thrombin stimulation consistently elicited a potent and efficacious mitogenic response. Thrombin-induced increases in DNA synthesis were evident at 24 h after stimulation. However, maximal effects were not observed until 48 h after stimulation (Fig. 3) . In contrast, PDGF-BB-stimulated increases in DNA synthesis in rat aortic SMC are maximal at 24 h after stimulation (25) . These results indicate that whereas a-thrombin itself is mitogenic, it may also stimulate production of secondary growth factors by SMC. Thrombin is known to stimulate PDGF production by endothelial cells (26) . Whereas SMC are known to produce a variety ofgrowth factors (27) (28) (29) , further studies are needed to determine the effects of thrombin on SMC growth factor production.
In additional experiments, r-hirudin, a specific thrombin inhibitor (30, 31 ) , selectively inhibited a-thrombin-induced mitogenesis in rat aortic SMC, but had no effect on the mitogenesis induced by 10% FBS or PDGF-BB (Fig. 2) . These data confirm and extend previous results reported by Bar-Shavit et al. (9) who showed that hirudin inhibited thrombin-induced, but not serum-induced, mitogenesis.
Thrombin-induced VSMC proliferation is dependent on its active site. To determine whether thrombin-induced mitogenesis was dependent on its active enzymatic site, derivatives of thrombin with alterations ofthe active site and the binding site were tested (Fig. 4) Our results demonstrating that the thrombin active site was required for mitogenesis in SMC are consistent with the hypothesis that the mitogenic effects in rat aortic SMC are mediated by a receptor similar or identical to that cloned by Vu et al. ( 16) and Rasmussen et al. ( 17) . To test this hypothesis further, rat aortic SMC were stimulated with the 14-amino acid synthetic thrombin receptor agonist peptide SFLLRNPNDKY-EPF. This peptide has been shown to be capable of activating the human thrombin receptor in a xenopus oocyte system, stimulating platelet aggregation and degranulation ( 16) , and stimulating mitogenesis in hamster lung fibroblasts (33) . A peptide containing the sequence FSLLRNPNDKYEPF was tested as a control. Results demonstrated that the 14-amino acid receptor agonist peptide was as efficacious as a-thrombin in stimulating proliferation of rat aortic SMC (Fig. 5 ), although at -1,000-10,000-fold the concentration ofa-thrombin. The difference in potency is likely related to the fact that the synthetic receptor agonist peptide is not tethered to the receptor, as is the ligand created by receptor cleavage with a-thrombin. Additionally, it does not possess the full anion-binding exosite, which is known (Fig. 6) .
Thrombin modulates the effects of other growth factors.
Vouret-Craviari et al. (34) reported that peptides derived from the newly exposed amino terminus of the hamster and human thrombin receptor activated phospholipase C, modulated adenylate cyclase, and stimulated platelets to release serotonin but did not induce mitogenesis in hamster fibroblasts (CCL39 cells) unless the cells had been co-treated with fibroblast growth factor or other tyrosine kinase-dependent growth factors, such as PDGF, endothelial cell-derived growth factor, and insulin. Thrombin has also been shown to potentiate the mitogenic response of cultured fibroblasts to growth-promoting agents such as fibroblast growth factor, endothelial cellderived growth factor, insulin, prostaglandins, and serum (35) . Our data clearly show that exogenous growth factors other than insulin, which is required for long-term survival of our cells in SFM, were not necessary for the peptide-induced mitogenic response in rat aortic SMC. However, we cannot rule out the possibility that thrombin and/or receptor peptide-induced growth in cultured SMC may be dependent on synergistic in-teraction with endogenously produced growth factors. SMC are known to produce growth factors such as PDGF-AA (27) , transforming growth factor-beta (TGF-f) (28) , and smooth muscle cell-derived growth factor( SDGF) (29) . It is thus possible that the mitogenic effects of thrombin in our SMC may be dependent on other growth factors that are produced constitutively by SMC or in response to thrombin treatment. Further studies will be needed to address these issues.
In summary, results demonstrate that thrombin was a potent and efficacious mitogen for cultured rat aortic SMC. Growth responses were dependent on the active site of thrombin and could be induced with a receptor peptide. This result suggests that the a-thrombin-induced growth effects in rat SMC were mediated by a receptor similar or identical to the human thrombin receptor. The vascular response to balloon angioplasty is complex and involves processes other than SMC proliferation (2) (3) (4) (5) . Moreover, results of cell culture experiments cannot be directly extrapolated to events in vivo. Nevertheless, results ofthe present study provide important information about the mechanisms whereby thrombin might contribute to SMC proliferation after angioplasty, and should permit design of thrombin receptor antagonists that could be tested in vivo for their ability to limit thrombin-stimulated SMC proliferation and postangioplasty restenosis.
